EQ vs KMDA vs PRTA vs ACAD vs CRL

For growth investors, Kamada Ltd.

(KMDA) is the stronger pick with 12. 1% revenue growth year-over-year, versus -100. 0% for Equillium, Inc. (EQ). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 2x trailing P/E (54. 2x forward), making it the more compelling value choice. Analysts rate Equillium, Inc. (EQ) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACADIA Pharmaceuticals Inc.

(ACAD) is the cheapest at 9. 2x versus Kamada Ltd. at 20. 1x. On forward P/E, Charles River Laboratories International, Inc. is actually cheaper at 16. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Kamada Ltd.

(KMDA) delivered a total return of +33. 7%, compared to -82. 7% for Prothena Corporation plc (PRTA). Over 10 years, the gap is even starker: CRL returned +122. 4% versus PRTA's -82. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Equillium, Inc.

(EQ) is the lower-risk stock at 0. 58β versus Prothena Corporation plc's 1. 50β — meaning PRTA is approximately 158% more volatile than EQ relative to the S&P 500. On balance sheet safety, Equillium, Inc. (EQ) carries a lower debt/equity ratio of 3% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Kamada Ltd.

(KMDA) is pulling ahead at 12. 1% versus -100. 0% for Equillium, Inc. (EQ). On earnings-per-share growth, the picture is similar: ACADIA Pharmaceuticals Inc. grew EPS 68. 4% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KMDA leads at 14. 5% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Charles River Laboratories International, Inc.

(CRL) trades at 16. 9x forward P/E versus 176. 7x for Prothena Corporation plc — 159. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRTA: 130. 3% to $19. 00.

In this comparison, KMDA (2.

9% yield) pays a dividend. EQ, PRTA, ACAD, CRL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Kamada Ltd.

(KMDA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 28), 2. 9% yield, +112. 7% 10Y return). Prothena Corporation plc (PRTA) carries a higher beta of 1. 50 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KMDA: +112. 7%, PRTA: -82. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: EQ is a small-cap quality compounder stock; KMDA is a small-cap quality compounder stock; PRTA is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock; CRL is a small-cap quality compounder stock. KMDA pays a dividend while EQ, PRTA, ACAD, CRL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.